H J Park1, K Kim2, J H Paik3, E K Chie4,5, S Kim4, J-Y Jang6, S W Kim6, S-W Han7, D-Y Oh7, S-A Im7, T-Y Kim7, Y-J Bang7, S W Ha4,5. 1. Department of Radiation Oncology, Hanyang University Hospital, Seoul, Republic of Korea. 2. Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Republic of Korea. kyubokim@snu.ac.kr. 3. Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea. 4. Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Republic of Korea. 5. Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, Republic of Korea. 6. Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea. 7. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Abstract
PURPOSE: To analyze the expression of c-Met, and to investigate correlations between the expression of c-Met, clinicopathologic variables, and survival in patients undergoing curative surgery followed by adjuvant chemoradiotherapy for extrahepatic bile duct (EHBD) cancer. METHODS: Ninety EHBD cancer patients who underwent curative resection followed by adjuvant chemoradiotherapy were enrolled. Expression of c-Met was assessed with immunohistochemical staining on tissue microarray. The correlation between clinicopathologic variables and survival outcomes was evaluated using Kaplan-Meier method and Cox proportional hazard model. RESULTS: On univariate analysis, 66 patients (76.7 %) showed c-Met expression. c-Met expression had a significant impact on 5-year overall survival (OS) (43.0 % in c-Met(+) vs. 25.0 % in c-Met(-), p = 0.0324), but not on loco-regional relapse-free survival or distant metastasis-free survival (DMFS). However, on multivariate analysis incorporating tumor location and nodal involvement, survival difference was not maintained (p = 0.2940). Tumor location was the only independent prognostic factor predicting OS (p = 0.0089). Hilar location tumors, nodal involvement, and poorly differentiated tumors were all identified as independent prognostic factors predicting inferior DMFS (p = 0.0030, 0.0013, and 0.0037, respectively). CONCLUSIONS: This study showed that c-Met expression was not associated with survival outcomes in EHBD cancer patients undergoing curative resection followed by adjuvant chemoradiotherapy. Further studies are needed to fully elucidate the prognostic value of c-Met expression in these patients.
PURPOSE: To analyze the expression of c-Met, and to investigate correlations between the expression of c-Met, clinicopathologic variables, and survival in patients undergoing curative surgery followed by adjuvant chemoradiotherapy for extrahepatic bile duct (EHBD) cancer. METHODS: Ninety EHBD cancerpatients who underwent curative resection followed by adjuvant chemoradiotherapy were enrolled. Expression of c-Met was assessed with immunohistochemical staining on tissue microarray. The correlation between clinicopathologic variables and survival outcomes was evaluated using Kaplan-Meier method and Cox proportional hazard model. RESULTS: On univariate analysis, 66 patients (76.7 %) showed c-Met expression. c-Met expression had a significant impact on 5-year overall survival (OS) (43.0 % in c-Met(+) vs. 25.0 % in c-Met(-), p = 0.0324), but not on loco-regional relapse-free survival or distant metastasis-free survival (DMFS). However, on multivariate analysis incorporating tumor location and nodal involvement, survival difference was not maintained (p = 0.2940). Tumor location was the only independent prognostic factor predicting OS (p = 0.0089). Hilar location tumors, nodal involvement, and poorly differentiated tumors were all identified as independent prognostic factors predicting inferior DMFS (p = 0.0030, 0.0013, and 0.0037, respectively). CONCLUSIONS: This study showed that c-Met expression was not associated with survival outcomes in EHBD cancerpatients undergoing curative resection followed by adjuvant chemoradiotherapy. Further studies are needed to fully elucidate the prognostic value of c-Met expression in these patients.
Entities:
Keywords:
Adjuvant chemoradiotherapy; Extrahepatic bile duct cancer; c-Met
Authors: Luis J Herrera; Talal El-Hefnawy; Pierre E Queiroz de Oliveira; Siva Raja; Sydney Finkelstein; William Gooding; James D Luketich; Tony E Godfrey; Steven J Hughes Journal: Neoplasia Date: 2005-01 Impact factor: 5.715
Authors: Uta Drebber; Stephan E Baldus; Britt Nolden; Guido Grass; Elfriede Bollschweiler; Hans P Dienes; Arnulf H Hölscher; Stefan P Mönig Journal: Oncol Rep Date: 2008-06 Impact factor: 3.906
Authors: Mi Hwa Heo; Hee Kyung Kim; Hansang Lee; Kyoung-Mee Kim; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Ho Yeong Lim; Won Ki Kang; Young Suk Park; Seung Tae Kim Journal: J Cancer Date: 2017-05-12 Impact factor: 4.207